SCYX
SCYNEXIS, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$5.31
−0.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 19.2M | 20.6M | 3.7M | 140.1M | 5.1M |
| Cost of Revenue | — | — | — | 15.6M | 628.0K |
| Gross Profit | 19.2M | 20.6M | 3.7M | 124.5M | 4.5M |
| Operating Expenses | |||||
| R&D Expense | 26.2M | 22.3M | 26.4M | 30.9M | 27.3M |
| SG&A Expense | 15.6M | 14.4M | 14.5M | 20.9M | 63.0M |
| General & Admin Expense | 4.1M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 41.8M | 36.7M | 40.9M | 51.8M | 90.2M |
| Cost and Expenses | 41.8M | 36.7M | 40.9M | 67.5M | 90.8M |
| Operating Income (EBIT) | (22.6M) | (16.1M) | (37.1M) | 72.7M | (85.8M) |
| Non-Operating | |||||
| Interest Income | 2.1M | 2.2M | 4.3M | 4.0M | 1.4M |
| Interest Expense | — | 173.0K | 2.6M | 6.1M | 6.8M |
| Net Interest Income | 2.1M | 2.0M | 1.7M | (2.2M) | (5.4M) |
| Other Non-Op Income/Expense | 12.4M | 7.5M | 16.0M | (5.5M) | 18.2M |
| Non-Operating Income (excl Interest) | (12.4M) | (7.6M) | (16.8M) | 2.4M | (25.0M) |
| EBT (Pre-Tax Income) | (10.2M) | (8.6M) | (21.1M) | 67.2M | (67.5M) |
| Income Tax Expense | — | — | 151.0K | 138.0K | (4.7M) |
| Bottom Line | |||||
| Net Income | (10.2M) | (8.6M) | (21.3M) | 67.0M | (62.8M) |
| Earnings from Cont. Ops | (10.2M) | (8.6M) | (21.3M) | 67.0M | (62.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (10.2M) | (8.6M) | (21.3M) | 67.0M | (62.8M) |
| Per Share | |||||
| Basic EPS | ($1.84) | ($1.38) | ($3.51) | $11.21 | ($11.79) |
| Diluted EPS | ($1.84) | ($1.38) | ($3.51) | $11.08 | ($11.79) |
| Revenue Per Share | $1.63 | $3.30 | $0.62 | $23.43 | $0.96 |
| Shares | |||||
| Basic Shares Outstanding | 11.8M | 6.2M | 6.1M | 6.0M | 5.3M |
| Diluted Shares Outstanding | 11.8M | 6.2M | 6.1M | 6.0M | 5.3M |
| Profitability Metrics | |||||
| EBITDA | (10.2M) | (8.1M) | (18.6M) | 70.9M | (59.9M) |
| D&A | — | 312.0K | 1.7M | 580.0K | 813.0K |
| EBIT | (10.2M) | (8.4M) | (20.3M) | 70.3M | (60.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026